Congress funds $75M brain tumor research push, expands patient trial access
S. 1330 — BRAIN Act · Filed by Richard Blumenthal (D-CT) · 9 cosponsors · Introduced Apr 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes $75 million over five years (2026–2030) for NIH-led research and public awareness programs focused on brain tumors and cancer treatment. It creates a searchable registry of biospecimen collections, funds a Glioblastoma Therapeutics Network ($50M) and CAR-T immunotherapy research ($10M), launches a national public awareness campaign on clinical trials and biomarker testing ($10M), funds pilot programs for brain tumor survivor care ($5M), and directs the FDA to issue guidance expanding brain tumor patient access to clinical trials. The bill benefits patients, researchers, and the public health system by improving treatment options, awareness, and long-term survivor care.
Why we flagged it
The bill is a straightforward appropriations and research authorization for NIH-led brain tumor research, clinical trial awareness, and survivor care. It contains no deregulation, liability shields, or private carve-outs—only public funding and public health infrastructure.
What the text implies
- The biospecimen registry may increase data-sharing efficiency but could raise privacy concerns if collection metadata is insufficiently de-identified or if researchers gain access without robust consent frameworks.
- The CAR-T and glioblastoma research programs may accelerate development of expensive immunotherapies; public funding here may subsidize later commercial deployment by pharma companies, though the bill does not explicitly grant IP rights to private parties.
- The FDA guidance on clinical trial inclusion for rare cancers may reduce exclusionary criteria, potentially expanding trial populations but also increasing trial complexity and cost.
- Pilot programs for survivor care may establish models later adopted by private health systems; the bill does not restrict private adoption or commercialization of successful models.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill directs public research funding toward a serious, underfunded disease area (brain tumors), expands patient access to clinical trials and biomarker testing through public awareness and FDA guidance, and establishes survivor care infrastructure. No private liability shields, tax carve-outs, or restrictions on citizen remedies are present; the bill is a straightforward public health investment.
Who stands to gain
- Academic medical centers and cancer research institutions (grant recipients)
- Pharmaceutical and biotechnology companies developing CAR-T and glioblastoma therapeutics (downstrea
- Health systems and community-based medical facilities (pilot program funding)
Named in the bill
National Institutes of Health (NIH), National Cancer Institute (NCI), FDA (Food and Drug Administration), Department of Health and Human Services (HHS), Academic medical centers, Cancer research institutions, Pharmaceutical companies (BMY, GH, PFE, JNJ, DVA mapped)
Where it stands
9 cosponsors: 6 Democrats, 3 Republicans.
- Apr 8, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Apr 8, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $5,703,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 61% of bills with at least one filing.
Richard Blumenthal, the sponsor, reported $111,550 in PAC receipts in the 2026 cycle.
- American Medical Association — $5,643,000 on 2 filings
- National Brain Tumor Society — $40,000 on 2 filings
- National Brain Tumor Society — $20,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (12,774 characters) on Aug 12, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress funds $75M brain tumor research push, expands patient trial access” QuorumCivic. https://share.quorumcivic.app/bill/119/s1330 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.